Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin.
The aim of this study was to evaluate the medium term effects of the selective alpha1-adrenenergic- blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally for 30 days. The daily dose was 1 mg for the first 7 days, 2 mg for the next 7 days and 5 mg for the remaining period of this clinical trial. At the end of this clinical trial, plasma ANP levels increased by 16.40% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that terazocin exerts part of its antihypertensive action by increasing ANP plasma levels.
Kotridis
P
P
Department of 2nd Cardiology, Medical School, Aristotle University of Thesssaloniki, Greece.
Kokkas
B
B
Kyriakou
P
P
Karamouzis
M
M
Salpigidis
G
G
Karantona
C
C
Karadoumanis
J
J
Ginis
T
T
Goulis
O
O
Papadopoulos
P C
PC
Vakalopoulos
C
C
Sakantamis
G
G
Dimitriadou
A
A
Mirtsou-Fidani
V
V
Papadopoulos
C L
CL
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D009320:Atrial Natriuretic Factor; C041226:Terazosin; D011224:Prazosin